IQVIA (NYSE: IQV), formerly known as QuintilesIMS, is a publicly owned American multinational company headquartered in the United States. Founded in 1982, the company has grown to employ over 72,660 people. IQVIA provides advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company offers a wide range of services, including data analytics, clinical trials management, and consulting services. IQVIA's clients include pharmaceutical and biotechnology companies, as well as government agencies and healthcare providers.
In 2023, Iqvia reported a shift in decision-making within the U.S. healthcare industry, with integrated networks such as GPOs, IDNs, and payers gaining more influence compared to individual physicians. This change has led to an increased emphasis on demonstrating the value of medical device and diagnostic solutions, with demands for outcomes analyses and pricing pressures. Additionally, Zacks revealed a report identifying potential growth stocks, including Iqvia Holdings Inc. (IQV), while RFP Financial Group held a minimal 0.00% stake in the company. Furthermore, a research report on the pharmacovigilance market provided insights into market size, regional shares, competitors, and detailed market share analysis.
Subscribe for full access to Iqvia's products in full detail 
